Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

@article{Lipton2006ParadigmSI,
  title={Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond},
  author={S. Lipton},
  journal={Nature Reviews Drug Discovery},
  year={2006},
  volume={5},
  pages={160-170}
}
  • S. Lipton
  • Published 2006
  • Chemistry, Medicine
  • Nature Reviews Drug Discovery
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological… Expand
View on Springer
ncbi.nlm.nih.gov
733 Citations
Highly Influential Citations
49
Background Citations
310
Methods Citations
15
Results Citations
16

733 Citations

Citation Type

Citation Type

NEUROPROTECTIVE STRATEGIES: DEVELOPMENT OF A CLINICALLY TOLERATED COMPOUND *
Recent insights into the mode of action of memantine and ketamine.
Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review.
Memantine in the treatment of Alzheimer’s disease
Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease
Design, synthesis, and evaluation of polyamine-memantine hybrids as NMDA channel blockers.
Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: Evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects
Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity
Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 117 REFERENCES
Potential and Current Use of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Diseases of Aging
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.
Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data
Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity
  • HS Chen, J. Pellegrini, +4 authors S. Lipton
  • Medicine
  • The Journal of neuroscience : the official journal of the Society for Neuroscience
  • 1992
Excitotoxity and the NMDA receptor
Pharmacological Implications of Two Distinct Mechanisms of Interaction of Memantine with N-Methyl-d-aspartate-Gated Channels
Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation
NMDA receptor pathways as drug targets
Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)
...
1
2
3
4
5
...